April 28, 2026
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors...
Read More
April 23, 2026
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...
Read More